NASDAQ:ACRX - AcelRx Pharmaceuticals Stock Price, Forecast & News

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) posted its earnings results on Wednesday, November, 6th. The specialty pharmaceutical company reported ($0.16) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.07. The specialty pharmaceutical company had revenue of $0.61 million for the quarter, compared to analyst estimates of $1.22 million. View AcelRx Pharmaceuticals' Earnings History.

AcelRx Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals issued an update on its FY 2019 Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $2.3-2.3 million, compared to the consensus revenue estimate of $2.82 million.

4 brokerages have issued 12 month price objectives for AcelRx Pharmaceuticals' stock. Their forecasts range from $2.00 to $10.00. On average, they anticipate AcelRx Pharmaceuticals' share price to reach $6.88 in the next twelve months. This suggests a possible upside of 337.9% from the stock's current price. View Analyst Price Targets for AcelRx Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AcelRx Pharmaceuticals.

Media coverage about ACRX stock has trended neutral recently, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. AcelRx Pharmaceuticals earned a coverage optimism score of 0.4 on InfoTrie's scale. They also gave media coverage about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for AcelRx Pharmaceuticals.

AcelRx Pharmaceuticals saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 10,800,000 shares, an increase of 6.9% from the January 15th total of 10,100,000 shares. Based on an average trading volume of 1,020,000 shares, the short-interest ratio is presently 10.6 days. Currently, 13.8% of the shares of the company are short sold. View AcelRx Pharmaceuticals' Current Options Chain.

Some companies that are related to AcelRx Pharmaceuticals include Arcus Biosciences (RCUS), MacroGenics (MGNX), Satsuma Pharmaceuticals (STSA), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX), Magenta Therapeutics (MGTA), BioSpecifics Technologies (BSTC), Puma Biotechnology (PBYI), Ardelyx (ARDX), Morphic (MORF), BioDelivery Sciences International (BDSI), Sinovac Biotech (SVA), Aptorum Group (APM), OrganiGram (OGI) and Innate Pharma (IPHYF).

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Amicus Therapeutics (FOLD), Novavax (NVAX), Inovio Pharmaceuticals (INO), TG Therapeutics (TGTX), Cyberark Software (CYBR), Agile Therapeutics (AGRX), Fitbit (FIT) and Synergy Pharmaceuticals (SGYP).

AcelRx Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include State Street Corp (1.74%), Cornerstone Capital Inc. (0.62%), Marshall Wace LLP (0.23%), UBS Group AG (0.16%), Mercer Global Advisors Inc. ADV (0.13%) and Barclays PLC (0.10%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Institutional Ownership Trends for AcelRx Pharmaceuticals.

ACRX stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Cedar Wealth Management LLC, New York State Common Retirement Fund, Mercer Global Advisors Inc. ADV, State Street Corp and Lincoln Capital Corp. View Insider Buying and Selling for AcelRx Pharmaceuticals.

ACRX stock was acquired by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Ahrens Investment Partners LLC, California Public Employees Retirement System, Cornerstone Capital Inc., UBS Group AG, Barclays PLC and Citigroup Inc.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View Insider Buying and Selling for AcelRx Pharmaceuticals.

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ACRX stock can currently be purchased for approximately $1.57.

AcelRx Pharmaceuticals has a market capitalization of $124.92 million and generates $2.15 million in revenue each year. The specialty pharmaceutical company earns $-47,150,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe.View Additional Information About AcelRx Pharmaceuticals.

The official website for AcelRx Pharmaceuticals is http://www.acelrx.com/.

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]